Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

NCT01405560 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Vaniprevir
BIOLOGICAL: peg-IFN
DRUG: ribavirin

Sponsor

Merck Sharp & Dohme LLC